Foresight Diagnostics
Dirigeants
Voir l'organigramme avec ses 12 principaux dirigeants
Biographies les plus recherchées chez Foresight Diagnostics
- Jake Chabon, Chief Executive Officer and Chief Scientific Officer
- Mark Lee, Board Member
- Shahram Seyedin-Noor, Director
Changements de dirigeants chez Foresight Diagnostics
- John Truesdell, a rejoint l'entreprise comme Chief Business Officer (publié le 18 août 2023).
Créer une alerte
pour suivre les mouvements de dirigeants chez Foresight Diagnostics.
Biotechnologie
Foresight Diagnostics a 2 292 concurrents dont Eurofins (Luxembourg), Lonza (Suisse) et Adaptive Phage Therapeutics (Etats—Unis).
Actualités en fusion/acquisition en Biotechnologie.
- Lycia Therapeutics vient d'annoncer une levée de fonds de 107 millions de dollars. (publié le 15 mai 2024).
- Attovia Therapeutics vient d'annoncer une levée de fonds de 150 millions de dollars. (publié le 14 mai 2024).
- Bruker has announced the acquisition of NanoString Technologies (publié le 13 mai 2024).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Foresight Diagnostics
- Foresight Diagnostic’s Co-Founder Dr. David Kurtz Joins Company as Chief Medical Officer and Head of Research
- Allogene Therapeutics, Foresight Diagnostics Partner to Develop MRD Test for CAR T-Cell Therapy Trial
- Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma (LBCL)
- Foresight Diagnostics and partners present twelve studies demonstrating accuracy and utility of PhasED-Seq ctDNA platform for early response assessment at the 65th American Society of Hematology (ASH) Annual Meeting
- Foresight Diagnostics Presents Four Presentations and Two Posters demonstrating accuracy and utility of PhasED-Seq ctDNA platform for early response assessment at the 65th American Society of Hematology (ASH) Annual Meeting
- Hodgkin lymphoma prognosis, biology tracked with circulating tumor DNA
- Foresight Diagnostics Announces Six Presentations Highlighting the Utility of PhasED-Seq™ for Early and Accurate MRD Detection at the 65th American Society of Hematology Annual Meeting
- Foresight Diagnostics Strengthens Leadership Team with Addition of Chief Business Officer John Truesdell
- Foresight Diagnostics Announces Study Demonstrating Prognostic Utility of PhasED-SeqTM for MRD Assessment after Frontline DLBCL Treatment at the 17th International Conference on Malignant Lymphoma
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Foresight Diagnostics
- Foresight Diagnostics sur Wikipédia, Google News & Yahoo Finance en 1-click
- Foresight Diagnostics sur LinkedIn, Twitter & YouTube en 1-click
Entrer en contact
Contacter par email ses dirigeants dont Jake Chabon 
Appelez Foresight Diagnostics au +91 810...
